{
    "nct_id": "NCT05900895",
    "official_title": "Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)",
    "inclusion_criteria": "* Post-menopausal women with ER+/HER2- breast cancer.\n* Metastatic or locoregional recurrence not amenable to treatment with curative intent.\n* Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* During study treatment, no concurrent anti-cancer therapies are allowed with the following exceptions:\n\n  o Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) permitted.\n* Any investigational cancer therapy or systemic chemotherapy in the last 3 weeks.\n* Any radiation therapy in the last 2 weeks.\n* Known CNS disease, unless clinically stable for ≥ 3 months.\n* Concomitant use of known strong or moderate CYP3A inhibitors.\n* Persistent toxicities (≥CTCAE grade 2) caused by previous cancer therapy.\n* History of any of the following:\n\n  * Deep venous thrombosis\n  * Pulmonary embolism\n  * Stroke\n  * Acute myocardial infarction\n  * Congestive heart failure\n  * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%\n  * Severe renal impairment (creatinine clearance ≤ 30 mL/min).",
    "miscellaneous_criteria": ""
}